risperidone IR and LAI formulation
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychotic Disorders
Conditions
Psychotic Disorders, Schizophrenia
Trial Timeline
Dec 1, 2008 → Jun 1, 2009
NCT ID
NCT00821600About risperidone IR and LAI formulation
risperidone IR and LAI formulation is a phase 1 stage product being developed by Johnson & Johnson for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00821600. Target conditions include Psychotic Disorders, Schizophrenia.
What happened to similar drugs?
2 of 7 similar drugs in Psychotic Disorders were approved
Approved (2) Terminated (4) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00821600 | Phase 1 | Completed |
Competing Products
14 competing products in Psychotic Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine, Amantadine + Olanzapine and placebo | Eli Lilly | Phase 1 | 29 |
| quetiapine | AstraZeneca | Phase 3 | 32 |
| Quetiapine | AstraZeneca | Phase 3 | 40 |
| Quetiapine | AstraZeneca | Phase 3 | 32 |
| quetiapine + olanzapine + risperidone | AstraZeneca | Pre-clinical | 26 |
| Asenapine 5-20 mg daily + Placebo 1-4 tablets daily | Merck | Approved | 43 |
| Ziprasidone HCL (oral) | Pfizer | Approved | 35 |
| Aripiprazole | Bristol Myers Squibb | Phase 3 | 40 |
| Aripiprazole + Risperidone/Quetiapine | Bristol Myers Squibb | Pre-clinical | 26 |
| mifepristone + placebo | Corcept Therapeutics | Phase 3 | 29 |
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 32 |
| Miricorilant + Fluvoxamine | Corcept Therapeutics | Phase 1 | 26 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 32 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 26 |